Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.

European journal of cancer (Oxford, England : 1990) - 1 Dec 2013

Rubovszky G, Láng I, Ganofszky E, Horváth Z, Juhos E, Nagy T, Szabó E, Szentirmay Z, Budai B, Hitre E

Abstract excerpt

PURPOSE: Biliary tract cancer is rare and has dismal prognosis. Chemotherapy has its role in inoperable disease but the role of targeted agents like cetuximab remains to be defined. On the basis of high epidermal growth factor receptor expression of biliary tract cancers this study aims to investigate the efficacy of cetuximab, gemcitabine and capecitabine in an exploratory phase 2 trial. PATIENTS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Cetuximab

Share to Deoxycytidine

Share to Exanthema

Share to Fatigue

Share to Gemcitabine

Source

Identifiers

PMID: 24007821
DOI: 10.1016/j.ejca.2013.07.143

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.PMID 24007821Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Semantic proximity Read ↗

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity Read ↗

Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations.Semantic proximity Read ↗

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Semantic proximity Read ↗

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Semantic proximity Read ↗

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read ↗

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case SeriesSemantic proximity Read ↗

Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity Read ↗

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Systemic treatment options for advanced biliary tract carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.